Abstract: The present invention is concerned with the use of aniline derivatives of the general formula: ##STR1## wherein R.sup.1 is a hydrogen atom or a --(CH.sub.2).sub.n --X radical, in which n is a whole number of from 1 to 3, X is H, OH, NH.sub.2, CH.sub.3 CONH, CH.sub.3 SO.sub.2 NH, COOH, SO.sub.3 H or --ArSO.sub.3 H, Ar being an optionally substituted arylene radical, m is a whole number of from 2 to 4, R.sup.3 is a hydrogen atom, an alkyl radical containing up to 3 carbon atoms, OCH.sub.3, CH.sub.3 CONH, COOH or SO.sub.3 H and R.sup.4 is a hydrogen, chlorine or bromine atom or a carboxylic acid or sulphonic acid group, as coupling components in oxidative color formation reactions.The present invention also provides an agent for the analytical determination of oxidizing substances by oxidative color coupling which, as coupling component, contains at least one compound of general formula (I).

Abstract: The present invention provides a process for the preparation of cystalline torasemide in the pure modification I (monoclinic, space group P2.sub.1 /c, melting point 162.degree. C.) from torasemide of modification II (monoclinic, space group P2/n, melting point 169.degree. C.), wherein a suspension of torasemide of modification II is stirred in water with the addition of a catalytic amount of modification I until the rearrangement is complete.The present invention also provides pharmaceutical compositions containing torasemide of modification I.

Abstract: The present invention provides a process for the preparation of crystalline torasemide in the pure modification I (monoclinic, space group P2.sub.1 /c, melting point 162.degree. C.) from torasemide of modification II (monoclinic, space group P2/n, melting point 169.degree. C.), wherein a suspension of torasemide of modification II is stirred in water with the addition of a catalytic amount of modification I until the rearrangement is complete.The present invention also provides a pharmaceutical compositions containing torasemide of modification I.

Abstract: The present invention provides a process for the preparation of crystalline torasemide in the pure modification I (monoclinic, space group P2.sub.1 /c, .[.melting point 162.degree. C.).]. .Iadd.in prism form) .Iaddend.from torasemide of modification II (monoclinic, space group P2/n, .[.melting point 169.degree..),.]. .Iadd.in leaflet form), .Iaddend.wherein a suspension of torasemide of modification II is stirred in water with the addition of a catalytic amount of modification I until the rearrangement is complete.The present invention also provides a pharmaceutical compositions containing .Iadd.stable .Iaddend.torasemide of modification I.

Abstract: The present invention provides a process for the preparation of cystalline torasemide in the pure modification I (monoclinic, space group P2.sub.1 /c, melting point 162.degree. C.) from torasemide of modification II (monoclinic, space group P2/n, melting point 169.degree. C.), wherein a suspension of torasemide of modification II is stirred in water with the addition of a catalytic amount of modification I until the rearrangement is complete.The present invention also provides pharmaceutical compositions containing torasemide of modification I.